Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors

Inclusion Criteria: * The patient or his/her guardian voluntarily signed the informed consent; * Age \>18 years and ≤70 years, male or female; * Patients with advanced solid tumors who have been confirmed by histopathology or cytology and have received at least first-line of treatment: 1. Recurrent/metastatic/persistent (persistent defined as disease progression after initial treatment) cervical cancer, including squamous cell carcinoma (SCC), adenosquamous carcinoma (ASC), and adenocarcinoma (AC), and not eligible for curative surgery and/or radiotherapy: 1. Recurrent/metastatic/persistent cervical cancer with prior failure (disease progression or intolerable toxicity) of at least 1 but no more than 3 systemic therapies; 2. Systemic therapy is defined as any chemotherapy or multi-drug combination chemotherapy regimen recommended by guidelines used for cervical cancer; 3. Chemotherapy or chemoradiotherapy administered as neoadjuvant or adjuvant therapy is not counted as a prior line of systemic therapy. 2. Or, classified as Stage Ⅳ cervical cancer according to the International Federation of Gynecology and Obstetrics (FIGO 2018) staging criteria (studies have shown that patients with early-stage cancer may have better outcomes after TIL therapy. After confirming significantly superior efficacy compared to marketed TIL products, researchers can relax staging criteria according to their judgment); 3. Histologically or cytologically confirmed locally advanced/metastatic liver malignancies (including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and metastatic liver cancer): 1. For hepatocellular carcinoma (HCC), classified as Barcelona Clinic Liver Cancer (BCLC) Stage C or Stage B unsuitable for local therapy or progressed after local therapy; 2. For locally advanced liver cancer, patients must have failed at least first-line systemic therapies recommended by guidelines (disease progression or intolerable toxicity); 3. Unresectable intrahepatic cholangiocarcinoma patients must have failed at least 1 but no more than 3 prior systemic therapies recommended by guidelines(disease progression or intolerable toxicity); 4. Metastatic liver cancer ineligible for curative surgery based on primary tumor TNM (Tumor Node Metastasis) staging; for metastatic liver cancer, patients must have failed at least 2 but no more than 3 guideline-recommended systemic therapies (disease progression or intolerable toxicity); 5. Liver function Child-Pugh score ≤7; 6. Or patients deemed by the investigator to be unsuitable for existing standard treatments, or who refuse standard therapy. 4. Advanced solid tumors that have progressed after prior standard therapy or are intolerant to toxicity, for which no standard treatment options are currently available, or for other reasons cannot receive the current standard treatment, including but not limited to primary or metastatic triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) (excluding neuroendocrine tumors or mixed types with \>10% neuroendocrine components), ovarian cancer (OC), head and neck cancer (HNC), and colorectal cancer (CRC). * The subject has residual lesions suitable for surgical resection (≥1.5 cm) or biopsy (core needle biopsy specimens: ≥4 passes with 16G needle or ≥6 passes with 18G needle) to generate tumor-infiltrating lymphocytes (TILs). For cervical cancer subjects, tumor tissue meeting either ≥0.5 cm in diameter or ≥400 mm³ in volume is acceptable. Fresh tumor tissue for TIL production should preferably be obtained from proximal metastatic lymph nodes or the periphery of tumor lesions. The sampled lesion has not received local therapy (e.g., radiotherapy, radiofrequency ablation, oncolytic virus, etc.) or such interventions have occurred ≥3 months prior and the lesion has progressed after local treatment; * Expected life expectancy ≥3 months; * After tumor resection/puncture, the subject must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) for efficacy evaluation; * Eastern Cooperative Oncology Group (ECOG) performance status was 0-1 (subjects with stable brain metastases require investigator assessment); * Adequate organ function: 1. Hematological (no transfusions, platelet infusions, or growth factor support \[except recombinant erythropoietin\] within 7 days prior to enrollment): 1. Absolute neutrophil count (ANC)≥1x10\^9/L; 2. Platelet count (PLT) ≥80 × 10\^9/L; 3. Hemoglobin (Hb) ≥90.0 g/L; 2. Blood chemistry: 1. Estimated creatinine clearance ≥40 mL/min (calculated by Cockcroft-Gault formula); 2. Alanine aminotransferase (ALT) ≤3 × upper limit of normal (ULN); 3. Aspartate aminotransferase (AST) ≤3 × ULN; 4. Total bilirubin (TBIL) ≤2 mg/dL (subjects with Gilbert-Meulengracht syndrome ≤3 mg/dL); 5. Serum AST and ALT ≤5 × ULN (subjects with liver metastasis); 3. Adequate pulmonary reserve defined as ≤Grade 1 dyspnea and oxygen saturation \>91% on room air; 4. Left ventricular ejection fraction (LVEF) ≥45% by echocardiography or multigated acquisition (MUGA) scan, with hemodynamic stability; * In the investigator's judgment, the subject must have recovered from prior anticancer therapy toxicities to Grade 1 or lower (except for specific Grade 2 or lower toxicities deemed irreversible in a short period of time as judged by the investigator, e.g., alopecia) and be eligible for preconditioning chemotherapy and TIL therapy; * Subjects with documented ≥Grade 2 diarrhea or colitis from prior immune checkpoint inhibitor therapy must be asymptomatic for ≥6 months before tumor resection, with normal colonoscopy (visual assessment) post-immunotherapy (excluding colorectal cancer patients); * Subjects with immune-related endocrinopathies (e.g., hypothyroidism) may enroll if stable for ≥6 weeks and controlled with hormone replacement therapy (non-corticostero